Piper Sandler Increases Humana (NYSE:HUM) Price Target to $288.00

Humana (NYSE:HUM) had its price target lifted by stock analysts at Piper Sandler from $270.00 to $288.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “neutral” rating on the insurance provider’s stock. Piper Sandler’s price target would indicate a potential upside of 4.32% from the company’s previous close.

A number of other brokerages also recently issued reports on HUM. KeyCorp assumed coverage on Humana in a research report on Friday, October 11th. They set a “sector weight” rating on the stock. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research report on Tuesday, October 8th. UBS Group dropped their target price on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research report on Friday, October 4th. Finally, Truist Financial upped their price target on shares of Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $302.70.

Humana Trading Down 1.2 %

Shares of NYSE:HUM opened at $276.08 on Wednesday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a 12-month low of $213.31 and a 12-month high of $455.53. The business has a 50 day moving average of $274.16 and a two-hundred day moving average of $308.90. The company has a market capitalization of $33.24 billion, a PE ratio of 24.45, a PEG ratio of 2.02 and a beta of 0.55.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, beating the consensus estimate of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, analysts forecast that Humana will post 16.14 EPS for the current year.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares in the company, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.32% of the stock is owned by company insiders.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Creative Financial Designs Inc. ADV grew its holdings in shares of Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the period. Atwood & Palmer Inc. purchased a new position in Humana during the third quarter worth about $29,000. Ashton Thomas Securities LLC purchased a new position in Humana during the third quarter worth about $31,000. Your Advocates Ltd. LLP increased its position in shares of Humana by 81.8% during the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares during the last quarter. Finally, Hollencrest Capital Management purchased a new stake in shares of Humana in the 2nd quarter valued at approximately $40,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.